Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: An open-label phase 3 trial (MIRAI)
Clinical and Experimental Rheumatology Online | Dec 08, 2019
Most read this week